Endo Presents Healthcare Provider Survey at Joint Meeting of International Society for the Study of Women's Sexual Health (ISSWSH) and International Society for Sexual Medicine (ISSM)

Rhea-AI Summary

Endo (OTCQX: NDOI) has announced a significant presentation at the joint meeting of the International Society for the Study of Women's Sexual Health (ISSWSH) and International Society for Sexual Medicine (ISSM), scheduled for February 27-March 2, 2025.

The presentation focuses on a healthcare provider survey regarding Peyronie's disease and its psychological impact on female partners. Led by urologist Dr. Irwin Goldstein, the study aims to evaluate healthcare providers' awareness and practices in addressing this condition.

The Endo-sponsored research titled 'Development of a Survey to Assess Women's Sexual Health Providers' Awareness and Approach Toward Peyronie's Disease and the Impact on the Female Sexual Partner' involves collaboration among multiple medical professionals and researchers in the field of sexual health.

MALVERN, Pa., Feb. 27, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today a presentation related to Peyronie's disease will be shared during the International Society for the Study of Women's Sexual Health (ISSWSH) and International Society for Sexual Medicine (ISSM) Joint Meeting, taking place February 27-March 2, 2025.

"I'm pleased to share this survey about the knowledge of women's sexual health care providers on the emotional and psychological impact that Peyronie's disease may have on female partners," said Dr. Irwin Goldstein, urologist and lead author of the study. "The insights we gather will allow us to assess providers' practices and awareness and enable us to identify opportunities to better support both healthcare professionals and their patients."

The Endo-sponsored presentation is below:

• Development of a Survey to Assess Women's Sexual Health Providers' Awareness and Approach Toward Peyronie's Disease and the Impact on the Female Sexual Partner
  • Authors: Irwin Goldstein, MD; Sue W. Goldstein, CSE, CCRC, IF; Rose Hartzell, PhD, EdS; Tami Rowen, MD; Sameena Rahman, MD; Becky Lynn, MD; Alyse Kelly-Jones, MD; David Hurley, MD; Gregory Kaufman, MD; Lisa Bathish, BA, PMP; Nicole Tay, BS; Sheryl Kingsberg, PhD

About Peyronie's Disease
Peyronie's disease (PD) is a condition in which a buildup of fibrous scar tissue causes a curvature deformity of the penis. This curvature can be bothersome during arousal and intimacy.¹ It is estimated that PD can affect as many as 1 in 10 men in the U.S.,² but diagnosis rates remain low because men with PD may be too uncomfortable to speak up and get help.³

PD in men may also have significant negative effects on sexual function and satisfaction for female sexual partners of patients with PD.⁴

About Endo
Endo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, the statements by Dr. Goldstein and any statements relating to product efficacy, potential treatments or indications, therapeutic outcomes or treatment responses, and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intends," "guidance," "future," "potential" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Endo may not currently be able to predict. Although Endo believes that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, the following: changes in competitive, market or regulatory conditions; changes in legislation or regulations; the ability to obtain and maintain adequate protection for intellectual property rights; the impacts of competition; the timing and uncertainty of the results of the research and development and the regulatory processes; health care and cost containment reforms, including government pricing, tax and reimbursement policies; litigation and other disputes; consumer and physician acceptance of current and new products; the performance of third parties upon whom we rely for goods and services; issues associated with our supply chain; the ability to develop and expand our product pipeline, to launch new products and to continue to develop the market for our products; and the effectiveness of advertising and other promotional campaigns. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in press releases issued by Endo and in Endo's public filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Endo's most recent Form 10-Q and in Endo's final prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, in connection with Endo's Form S-1/A.

References:

1. Hellstrom WJ. Int J Impot Res. 2003;15:S91-S92.
2. Stuntz M, Perlaky A, des Vignes F, et al. PLoS One. 2016;11(2):e0150157.
3. DiBenedetti DB, Nguyen D, Zografoset L, et al. Adv Urol. 2011:282503.
4. Davis SN, Ferrar S, et al. J Sex Med. 2016;13(7):1095-103.

View original content to download multimedia:https://www.prnewswire.com/news-releases/endo-presents-healthcare-provider-survey-at-joint-meeting-of-international-society-for-the-study-of-womens-sexual-health-isswsh-and-international-society-for-sexual-medicine-issm-302387976.html

SOURCE Endo, Inc.

FAQ

What is the focus of Endo's (NDOI) presentation at the ISSWSH-ISSM Joint Meeting 2025?

The presentation focuses on a healthcare provider survey examining awareness of Peyronie's disease and its emotional impact on female partners.

When is the ISSWSH and ISSM Joint Meeting where Endo (NDOI) will present their findings?

The joint meeting takes place from February 27 to March 2, 2025.

Who is leading the Endo (NDOI) sponsored research on Peyronie's disease?

Dr. Irwin Goldstein, a urologist, is the lead author of the study.

What is the main objective of Endo's (NDOI) healthcare provider survey?

The survey aims to assess providers' practices and awareness to identify opportunities for better supporting healthcare professionals and their patients affected by Peyronie's disease.